

Dwaipayan Mukherjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4271710/publications.pdf>

Version: 2024-02-01

14
papers

285
citations

1039406

9
h-index

1125271

13
g-index

14
all docs

14
docs citations

14
times ranked

467
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 770-781.	2.3	15
2	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. <i>Biopharmaceutics and Drug Disposition</i> , 2022, 43, 98-107.	1.1	4
3	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	2.3	21
4	Dose adjustment of venetoclax when co-administered with posaconazole: clinical drugâ€“drug interaction predictions using a PBPK approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 465-474.	1.1	21
5	Physiologicallyâ€“Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediatedâ€“Drugâ€“Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1082-1115.	2.3	88
6	In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities. <i>AAPS PharmSciTech</i> , 2019, 20, 243.	1.5	5
7	Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 443-456.	0.8	17
8	Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid. <i>Nanomaterials</i> , 2015, 5, 1223-1249.	1.9	6
9	Modeling<i>In Vitro</i> Cellular Responses to Silver Nanoparticles. <i>Journal of Toxicology</i> , 2014, 2014, 1-13.	1.4	12
10	Modeling population exposures to silver nanoparticles present in consumer products. <i>Journal of Nanoparticle Research</i> , 2014, 16, 1.	0.8	33
11	Modeling physicochemical interactions affecting in vitro cellular dosimetry of engineered nanomaterials: application to nanosilver. <i>Journal of Nanoparticle Research</i> , 2014, 16, 2616.	0.8	21
12	Physiologically-Based Toxicokinetic Modeling of Zearalenone and Its Metabolites: Application to the Jersey Girl Study. <i>PLoS ONE</i> , 2014, 9, e113632.	1.1	33
13	Computational Multiscale Toxicodynamic Modeling of Silver and Carbon Nanoparticle Effects on Mouse Lung Function. <i>PLoS ONE</i> , 2013, 8, e80917.	1.1	9
14	An Analytical Method for Quantifying Transport and Reaction of Anti-Tumor Drugs in Human Tissues. <i>Journal of Chemical Engineering of Japan</i> , 2009, 42, S226-S233.	0.3	0